title: Therapeutic effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, caffeic acid oxidation product, and trisodiumphosphonoformate on cutaneous herpes simplex virus type 1 infection in guinea pigs.
abstract: The influence of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), caffeic acid oxidation product (KOP), and trisodiumphosphonoformate (TPF) on the course of the primary cutaneous herpes simplex virus infection was investigated by means of a guinea pig test model. The antiviral substances were applied in an ointment with 10% urea as a penetration mediator. When the treatment was initiated 15 minutes after virus inoculation, 3% BVDU effectively inhibited the development of herpetic vesicles and 0.1% BVDU prevented the appearance of herpetic satellites. Under the same conditions 1% and 3% KOP ointments inhibited the appearance of satellites; and 0.5% TPF ointment completely inhibited the development of cutaneous herpes lesions. Prophylactic drug administration given 24, 20, and 4 hours before virus inoculation was without any protective effect.
authors.affiliation: Institute of Medical Microbiology, Medical Academy Erfurt, German Democratic Republic.
authors.forename: B
authors.initials: B
authors.lastname: Helbig
authors.forename: A
authors.initials: A
authors.lastname: Sauerbrei
authors.forename: R
authors.initials: R
authors.lastname: Klöcking
authors.forename: P
authors.initials: P
authors.lastname: Wutzler
authors.forename: N
authors.initials: N
authors.lastname: Wicht
authors.forename: U
authors.initials: U
authors.lastname: Wiedemann
authors.forename: G
authors.initials: G
authors.lastname: Herrmann
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D001973:Bromodeoxyuridine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002109:Caffeic Acids / Q000627:therapeutic use*; D002934:Cinnamates / Q000627:therapeutic use*; D005260:Female; D017245:Foscarnet; D006168:Guinea Pigs; D006561:Herpes Simplex / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010084:Oxidation-Reduction; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*; D018139:Simplexvirus / Q000302:isolation & purification
chemical_list: D000998:Antiviral Agents; D002109:Caffeic Acids; D002934:Cinnamates; D009943:Organophosphorus Compounds; C020235:brivudine; D017245:Foscarnet; D001973:Bromodeoxyuridine; D010746:Phosphonoacetic Acid; C040048:caffeic acid